CU22997A3 - Proteína híbrida para la inhibición de la desgranulación de los mastocitos y su utilización - Google Patents

Proteína híbrida para la inhibición de la desgranulación de los mastocitos y su utilización

Info

Publication number
CU22997A3
CU22997A3 CU20000234A CU20000234A CU22997A3 CU 22997 A3 CU22997 A3 CU 22997A3 CU 20000234 A CU20000234 A CU 20000234A CU 20000234 A CU20000234 A CU 20000234A CU 22997 A3 CU22997 A3 CU 22997A3
Authority
CU
Cuba
Prior art keywords
mastocits
degranulation
inhibition
hybrid protein
basophils
Prior art date
Application number
CU20000234A
Other languages
English (en)
Inventor
Juergen Frevert
Hans Bigalke
Original Assignee
Biotecon Ges Fuer Biotechnologische Entwicklung Und Consulting Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Ges Fuer Biotechnologische Entwicklung Und Consulting Mbh filed Critical Biotecon Ges Fuer Biotechnologische Entwicklung Und Consulting Mbh
Publication of CU22997A3 publication Critical patent/CU22997A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Fire-Extinguishing Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a una proteína híbrida que comprende o consta de (i) una proteína conocida de por sí que se une de una forma conocida de por sí a mastocitos y/o basófilos y/o es ligada por estos, y (ii) una proteasa conocida de por sí que hidroliza una o más proteínas del aparato de secreción de los mastocitos y/o basófilos.
CU20000234A 1998-05-13 2000-10-30 Proteína híbrida para la inhibición de la desgranulación de los mastocitos y su utilización CU22997A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19821285 1998-05-13

Publications (1)

Publication Number Publication Date
CU22997A3 true CU22997A3 (es) 2004-10-12

Family

ID=7867540

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20000234A CU22997A3 (es) 1998-05-13 2000-10-30 Proteína híbrida para la inhibición de la desgranulación de los mastocitos y su utilización

Country Status (22)

Country Link
EP (1) EP1084146B1 (es)
JP (1) JP4549533B2 (es)
KR (1) KR100580541B1 (es)
CN (1) CN1241945C (es)
AT (1) ATE227739T1 (es)
AU (1) AU755513B2 (es)
BR (1) BR9910359A (es)
CA (1) CA2331274C (es)
CU (1) CU22997A3 (es)
CZ (1) CZ294376B6 (es)
DE (1) DE59903410D1 (es)
DK (1) DK1084146T3 (es)
ES (1) ES2187200T3 (es)
HK (1) HK1036994A1 (es)
HU (1) HUP0103601A3 (es)
IL (2) IL139478A0 (es)
MX (1) MXPA00011148A (es)
NO (1) NO328361B1 (es)
PL (1) PL201879B1 (es)
PT (1) PT1084146E (es)
RU (1) RU2214420C2 (es)
WO (1) WO1999058571A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
CA2413301A1 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
KR100845278B1 (ko) * 2006-08-04 2008-07-09 포항공과대학교 산학협력단 비만 세포의 활성을 유도하는 펩타이드 및 이를 포함하는면역조절제
EP2719392B1 (en) 2008-06-12 2019-07-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
RU2525194C2 (ru) * 2008-07-31 2014-08-10 Тотал Маркетинг Сёрвисез Конструкции и способы для продуцирования и секреции ферментов, расщепляющих клеточную стенку
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN102241774B (zh) * 2010-05-27 2014-05-14 四川大学 重组IgE-Fc-抗EGFR单链抗体融合蛋白及其制备方法和用途
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
EP3242884B1 (en) 2015-01-09 2021-02-24 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
AU2021438810A1 (en) 2021-03-30 2023-09-21 Ipsen Biopharm Limited Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
AU2022247196A1 (en) 2021-03-30 2023-10-05 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
PL244930B1 (pl) 2021-12-08 2024-04-02 Gdanski Univ Medyczny Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
CA2331274C (en) 2010-04-06
CA2331274A1 (en) 1999-11-18
DE59903410D1 (de) 2002-12-19
RU2214420C2 (ru) 2003-10-20
EP1084146B1 (de) 2002-11-13
AU755513B2 (en) 2002-12-12
KR20010042825A (ko) 2001-05-25
NO328361B1 (no) 2010-02-01
EP1084146A2 (de) 2001-03-21
BR9910359A (pt) 2001-01-09
CZ294376B6 (cs) 2004-12-15
CN1300295A (zh) 2001-06-20
ATE227739T1 (de) 2002-11-15
IL139478A (en) 2008-06-05
WO1999058571A3 (de) 2000-02-03
WO1999058571A2 (de) 1999-11-18
PT1084146E (pt) 2003-02-28
NO20005637D0 (no) 2000-11-08
KR100580541B1 (ko) 2006-05-16
HUP0103601A2 (hu) 2002-01-28
AU4260599A (en) 1999-11-29
JP4549533B2 (ja) 2010-09-22
DK1084146T3 (da) 2003-02-03
JP2002514659A (ja) 2002-05-21
ES2187200T3 (es) 2003-05-16
IL139478A0 (en) 2001-11-25
PL201879B1 (pl) 2009-05-29
NO20005637L (no) 2000-11-08
CN1241945C (zh) 2006-02-15
HUP0103601A3 (en) 2004-06-28
CZ20004161A3 (cs) 2001-04-11
PL344752A1 (en) 2001-11-19
HK1036994A1 (en) 2002-01-25
MXPA00011148A (es) 2003-04-22

Similar Documents

Publication Publication Date Title
CU22997A3 (es) Proteína híbrida para la inhibición de la desgranulación de los mastocitos y su utilización
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
CY1112267T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
TR200100605T2 (tr) Arilpiperazinler ve bunların metaloproteinaz inhibe edici maddeler (MMP) olarak kullanımı
DK1094816T3 (da) Biphenylsulfonamider som dobbelte angiotensin-endothelin-receptorantagonister
BR9812371A (pt) Tratamento de distúrbio de conduta
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
ATE243993T1 (de) Verwendung von 5ht3 antagonisten zum fördern der darmspülung
ATE281431T1 (de) Resorcin-derivate
BR9811948A (pt) Secretores de hormÈnio do crescimento
ATE294164T1 (de) Fluoreszenzfarbstoffe zum festphasen- und flüssigphasen-screening
DOP2001000219A (es) Applicator
ES2193197T3 (es) Craquizacion catalitica com mcm-49.
AR009819A1 (es) Inhibidores de la proteasa proteinicos estabilizados y sus variantes
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
BR0110902A (pt) Inibidores de mmp-9/mmp-2
ECSP034604A (es) Inhibicion de la dependendia de celulas tumorales del factor de crecimiento
BR0110206A (pt) Inibidores de peptìdeo deformilase
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
DK1054892T3 (da) Azolpeptidmimetiske forbindelser som thrombinreceptorantagonister
DK0841937T3 (da) Anvendelse af betaglycan til reduktion af ardannelse
NO20044186L (no) Peptid-deformylaseinhibitorer
ATE433953T1 (de) Peptiddeformylaseinhibitoren

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)